Background: Currently, there is no approved treatment for the management of COVID-19 pandemic. Drug repurposing of existing medications could be a possible way to find out a novel therapeutic entity to combat the COVID-19.Objectives: To determine the clinical effectiveness and safety profile of an Ayurveda Intervention (Guduchighan Vati) in asymptomatic and mild to moderate cases of COVID-19.Methods: This was an open-label randomized controlled pilot study with a sample size of 30 participants (15 in each arm). The participants were asymptomatic or mild to moderate cases of COVID-19. Guduchighan Vati 500 mg twice daily for 10 days was administered in the intervention group as standalone therapy and Hydroxychloroquine in the control group.Outcome measures: Time to negative RT-PCR for COVID-19, proportion of participants turned RT-PCR negative for COVID-19 at 5th and 10th day, duration to achieve complete clinical recovery, improvement in laboratory parameters and incidence of Adverse Drug Reaction/Adverse Event. The data was compared within group using paired sample t-test/ Wilcoxon signed rank test and between group using independent sample t-test/Mann-Whitney test. The results of RT-PCR test was compared between group using chi-square test.Results: 93.3% participants turned RT-PCR negative for COVID-19 in the intervention group, as compared to 66.6% participants in control group till 10th day of the study period. However, the results are statistically insignificant (p = 0.068) which might be attributed to smaller sample size. All the symptomatic patients in the intervention group were clinically recovered at 5th day whereas 14 out of 15 recovered in the control group. No symptoms were observed at 10th day in both the groups. No adverse drug reaction/serious adverse event were observed during the study period.Conclusion: Guduchighan Vati is a safe and effective treatment for asymptomatic and mild cases of COVID-19 and it lowers the time to RT-PCR negative status without any adverse drug reaction/adverse event.

Thrombosis is one of the major causes of morbidity and mortality in a wide range of cardiovascular disorders (CVDs). CVDs are listed among top ten killer diseases. Antithrombotic drugs reduce the incidence of cardiovascular events about 20%–25% in people. Due to the high prevalence of thrombotic disorders, researches are being carried out on novel antithrombotic agents with minimal adverse effects in which herbal drugs are considered as alternative remedy. Medicinal plants have been used for the management of ailments since ancient times. The objective of this study is to do documentations the effect of herbal drugs on antithrombotic therapy. Herbal remedies are used to treat a large variety of thrombotic disorders. However, a number of herbal preparations have been reported to cause variations in clotting time, bleeding time, prothrombin time, activated partial thromboplastin time, thrombin time, fibrinogen, D-dimer, protein C, TXA2, etc. This is mainly by disruption of the coagulation cascade and platelet plug formation. This review can help to design future researches for antithrombotic drugs discovery with more effectiveness and safety. The reported antithrombotic drugs have the potential of improving quality of life while avoiding the side effects of conventional treatment. Data were collected by existing article on antithrombotic studies from various search engines. This review is focused on plants like Syzygium cumini L. Morus alba L., Zingiber officinal Roscoe, Allium cepa L., Nigella sativa L., Punica granatum L., Mentha longifolia L., Allium sativa L., Boswellia serrate Roxb. and Sesamum indicum L.

No abstract

Background: Currently, there is no approved treatment for the management of coronavirus disease (COVID-19). Drug repurposing of existing medications could be a possible way to find out a novel therapeutic entity to combat the COVID-19. Aim: To determine the clinical efficacy and safety of an Ayurveda intervention ( Guduchighana Vati ) in asymptomatic and mild-to-moderate cases of COVID-19. Materials and methods: This was an open-label randomized controlled pilot study with a sample size of 30 participants (15 in each arm). The participants were asymptomatic or mild to moderate cases of COVID-19. Guduchighana Vati 500 mg twice daily for 10 days was administered in the study group and Hydroxychloroquine for 5 days in the control group. Paracetamol, Vitamin C, Multivitamin, and Zinc were also provided in the control group. The main outcome measures were to negative real-time reverse transcription–polymerase chain reaction (RT-PCR) assay for COVID-19, proportion of participants with negative RT-PCR for COVID-19 at 5 th and 10 th day, proportion of participants with clinical recovery, improvement in laboratory parameters, and incidence of adverse drug reaction/adverse event (ADR/AE). The results of RT-PCR and clinical recovery were compared between groups using Chi-square test. The data related to laboratory parameters were compared within group using paired sample t -test/Wilcoxon signed-rank test and between groups using independent sample t -test/Mann–Whitney test. Results: The proportion of participants with negative RT-PCR for COVID-19 in the Guduchighana Vati group (93.3%) was better as compared to the control group (66.6%) till 10 th day of the study period. Though, the results are statistically not significant ( P = 0.068). All the symptomatic patients in the Guduchighana Vati group clinically recovered whereas one patient remained symptomatic in the control group on the 5 th day. No symptoms of COVID-19 were observed at 10 th day in both the groups. No ADR/serious adverse event were observed during the study period in either of the groups. Conclusion: In this study on asymptomatic and mild to moderate cases of COVID-19, Guduchighana Vati showed numerically better proportion of participants with negative RT-PCR assay for COVID-19 and reduced time to clinical improvement which requires confirmation through studies with larger sample size. Although, the study outcomes are statistically not significant which may be due to small sample size.

Introduction: The clinical features of the COVID-19 disease range from asymptomatic to mild–moderate symptoms. Owing to the severity and sudden onset of the disease, cases need hospital-based care. Several treatment protocols and strategies have been promoted and recommended by authorities including WHO, but nothing has actually been finalized to date. The present study was carried to evaluate the effectiveness of an Ayurvedic formulation, namely Arogya Kashayam-20 as an add-on to standard care in hospitalized cases of COVID-19. Materials and Methods: The study was a randomized controlled trial carried out at COVID Care Centre, xxxxxx with a sample size of 112 participants, aged between 16 and 60 years of either sex into two groups, namely, groups A and B. Both the groups received hydroxychloroquine, Vitamin C, and zinc as per the prevailing ICMR guidelines, and group “A” received additional Arogya Kashayam-20 for a 10-day duration. The outcome of the study was to see the negative conversion reverse transcription–polymerase chain reaction (RT-PCR) test after this duration. Results: Among the 60 cases in the study group (group A), 51 cases (85.00%) were reported with negative RT-PCR on the 10th day. Out of 52 cases registered in the control group (group B), 39 cases (75.00%) tested negative for RT-PCR. In both, groups all the cases were discharged asymptomatically on the 10th day as per the prevailing ICMR guidelines. No ADR/AE was reported during the period. Conclusion: The study observes that the add-on intervention group has a better outcome in terms of RT-PCR negative reports after 10 days compared to the control group.